ActiveSpans 9 functions
Updated Cannabis Industry Cashes In: Trump-Era Rescheduling Sparks Profit Surge, Wall Street Rush, and Research Boom—But Social Justice Lags
Federal cannabis reclassification is turning a capital-starved sector into a profit engine—while leaving old harms intact.
What is this trend?
Moving medical cannabis into Schedule III is easing tax and financing pressure, boosting profitability and investment, and opening research pathways even as criminal-justice repair remains unfinished.
- Section 280E relief is improving margins and cash flow across the industry.
- Better economics are drawing institutional capital, valuations, and consolidation.
- Clearer federal status is easing banking, licensing, and market-access frictions.
- Research barriers are falling, enabling more clinical and federally backed studies.
- Social justice fixes like expungement and broader repair are still largely absent.
What’s the latest?
Cannabis real estate is booming as federal rescheduling sparks bold deals, innovative financing, and strategic acquisitions among major REITs.
How it developed earlier updates
Cannabis just scored a Wall Street windfall as Trump-era rescheduling slashes taxes, unlocks research, and attracts big money—while social justice takes a back seat.
Cannabis Industry Cashes In: Trump-Era Rescheduling Sparks Profit Surge, Wall Street Rush, and Research Boom—But Social Justice Lags